The Renin Academy Summit: Advancing the understanding of renin science

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 2, 2008, Pages 119-123

  Danser, A H Jan ^a   Nguyen, Genevive ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HANDLE REGION PEPTIDE; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRORENIN; PRORENIN RECEPTOR; PROTEIN P85; RAMIPRIL; RECEPTOR; RENIN; RENIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG SAFETY; DRUG SYNTHESIS; EMBRYO DEVELOPMENT; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MEDICAL RESEARCH; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIMARY PREVENTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; RECEPTORS, CELL SURFACE; RENIN; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 47349115687     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2008.020     Document Type: Conference Paper

References (30)

1. Burcklé CA, Jan Danser AH, Müller DN et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006;47:552-6.
2. Kaneshiro Y, Ichihara A, Sakoda M et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007;18:1789-95.
3. Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93:557-63.
4. Danser AH, van den Dorpel MA, Deinum J et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989; 68:160-7.
5. Danser AH, van Kesteren CA, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997; 96:220-6.
6. Deinum J, Rønn B, Mathiesen E et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42:1006-10.
7. Peters B, Grisk O, Becher B et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26:102-09.
8. Mercure C, Prescott G, Lacomabe M-J et al. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. JRAAS 2008;9(Suppl 1):S4. doi:10.3317/ jraas.2008.010.
9. Derkx FH, Schalekamp MP, Schalekamp MA. Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin. J Biol Chem 1987;262:2472-7.
10. Mercure C, Thibault G, Lussier-Cacan S et al. Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 1995;270:16355-9.
11. Suzuki F, Hayakawa M, Nakagawa T et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 2003;278:22217-22.
12. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114:1128-35.
13. Uddin MN, Nabi AH, Nakagawa T et al. Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, "decoy peptide". Front Biosci 2008; 13:745-53.
14. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.
15. Feldt S, Maschke U, Dechend R et al. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008;19:743-8.
16. Takahashi H, Ichihara A, Kaneshiro Y et al. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007;18:2054-61.
17. Satofuka S, Ichihara A, Nagai N et al. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007; 48:422-9.
18. Oh BH, Mitchell J, Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63.
19. Andersen K, Weinberger MH, Egan B et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26:589-99.
20. Persson F, Rossing P, Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008 Ma 12 [Epub ahead of print].
21. Feldman DL, Persohn E, Schutz H et al. Renal localisation of the renin inhibitor aliskiren. J Clin Hypertens 2006;8:A80-A81 (P-178).
22. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008 [in press].
23. Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.
24. Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. JRAAS 2007; 8:190-8.
25. Oparil S, Yarrows, S, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9.
26. Parving H-H, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren in the evaluation of proteinuria in diabetes (AVOID). Abstract and poster #SA-PO1051 presented at American Society of Nephrology Renal Week, San Francisco, USA. 3 November 2007.
27. McMurray JJV. Haemodynamic, neurohumoral, renal and ambulatory electrocardiographic effects of a new oral renin inhibitor in stable heart failure. Oral presentation at European Society of Cardiology Congress, Vienna, Austria. 1-5 September 2007.
28. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.
29. Batenburg WW, de Bruin RJ, van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-7.
30. Nussberger J, Aubert JF, Bouzourene K et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51:1306-11.